The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells

被引:260
作者
Asano, T [1 ]
Yao, YX [1 ]
Zhu, JJ [1 ]
Li, DH [1 ]
Abbruzzese, JL [1 ]
Reddy, SAG [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
关键词
pancreatic cancer; PI; 3-kinase; Akt; NF-kappa B; c-Myc; PTEN;
D O I
10.1038/sj.onc.1207902
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The persistent activation of signaling cascades results in dramatic consequences that include loss of cellular growth control and neoplastic transformation. We show here that phosphoinositide 3-kinase (PI 3-kinase) and its mediator Akt were constitutively activated in pancreatic cancer and that this might be due to the aberrant expression of their natural antagonist MMAC/PTEN. Indeed, our results show that MMAC/PTEN expression was either lost or significantly reduced in five of eight cell lines and in twelve of seventeen tumor specimens examined. That the poor expression of MMAC/PTEN in pancreatic cancer cells could be due to promoter methylation was indicated by methylation-specific PCR analysis. Our studies also indicated that PI 3-kinase targeted two important transcription factors in pancreatic cancer cells. The ability of constitutively activated NF-kappaB to induce gene expression and the stabilization of c-MYC protein by decreased phosphorylation of Thr58 were both dependent on PI 3-kinase activity. When pancreatic cancer cells were treated with a peptide antagonist of NF-kappaB nuclear translocation, or stably transfected with a dominant-negative mutant of MYC, their proliferation was markedly inhibited. Taken together, these data indicate that the aberrant expression of MMAC/PTEN contributes to the activation of the PI 3-kinase/Akt pathway and its transcription factor mediators in pancreatic cancer.
引用
收藏
页码:8571 / 8580
页数:10
相关论文
共 57 条
  • [21] Kolenko V, 1999, J IMMUNOL, V163, P590
  • [22] Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFκB activation without interfering with the IκB degradation pathway
    Koul, D
    Yao, YX
    Abbruzzese, JL
    Yung, WKA
    Reddy, SAG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) : 11402 - 11408
  • [23] PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
    Li, J
    Yen, C
    Liaw, D
    Podsypanina, K
    Bose, S
    Wang, SI
    Puc, J
    Miliaresis, C
    Rodgers, L
    McCombie, R
    Bigner, SH
    Giovanella, BC
    Ittmann, M
    Tycko, B
    Hibshoosh, H
    Wigler, MH
    Parsons, R
    [J]. SCIENCE, 1997, 275 (5308) : 1943 - 1947
  • [24] CURRENT MANAGEMENT OF PANCREATIC-CARCINOMA
    LILLEMOE, KD
    [J]. ANNALS OF SURGERY, 1995, 221 (02) : 133 - 148
  • [25] Molecular pathology of invasive carcinoma
    Longnecker, DS
    [J]. CELL AND MOLECULAR BIOLOGY OF PANCREATIC CARCINOMA: RECENT DEVELOPMENTS IN RESEARCH AND EXPERIMENTAL THERAPY, 1999, 880 : 74 - 82
  • [26] The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
    Maehama, T
    Dixon, JE
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (22) : 13375 - 13378
  • [27] Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane
    Maira, SM
    Galetic, I
    Brazil, DP
    Kaech, S
    Ingley, E
    Thelen, M
    Hemmings, BA
    [J]. SCIENCE, 2001, 294 (5541) : 374 - 380
  • [28] Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo
    Mills, GB
    Lu, YL
    Kohn, EC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) : 10031 - 10033
  • [29] Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers
    Mutter, GL
    Lin, MC
    Fitzgerald, JT
    Kum, JB
    Baak, JPA
    Lees, JA
    Weng, LP
    Eng, C
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (11): : 924 - 931
  • [30] Nagy A, 2001, ANTICANCER RES, V21, P1321